

## Special Issue

# Monoclonal Antibodies for Targeted Biological Treatment of Severe Asthma

### Message from the Guest Editor

Asthma is a chronic respiratory disorder consisting of usually variable bronchial obstruction and hyperresponsiveness. Several endotypes play a crucial role in the pathobiology of asthma, causing heterogeneous clinical manifestations. Within this context, many targets for biological treatment of severe asthma, such as immunoglobulins E (IgE), pro-inflammatory cytokines and their receptors, have been identified. Specifically, omalizumab (anti-IgE), mepolizumab (anti-IL-5), reslizumab (anti-IL-5), benralizumab (anti-IL-5 receptor) and dupilumab (anti-IL-4/IL-13 receptors) are available in clinical practice, providing excellent clinical and functional effects even in a real-life environment. Furthermore, other biologics that target innate cytokines, such as IL-33 and thymic stromal lymphopoietin (TSLP), are under development. The aim is implementing phenotype/endotype-specific treatments, in order to delineate a personalized therapeutic approach tailored on the patient and chosen on the basis of existing and emerging biomarkers.

### Guest Editor

Dr. Corrado Pelaia

Department of Health Sciences, University "Magna Græcia" of Catanzaro, Catanzaro, Italy

### Deadline for manuscript submissions

closed (28 February 2022)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/88089](https://mdpi.com/si/88089)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).